Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up

Zacks11-06

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481989127?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4lmvToGK4d2FNc0SIOXMvw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/51f0c2cd09522c9a15cba48260e4facf","is_english":true,"pubTime":"2024-11-06 22:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481989127","market":"us","top_or_hot":-1,"title":"Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up","media":"Zacks","content":"<div>\n<p>Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share....</p>\n\n<a href=\"https://finance.yahoo.com/news/catalents-stock-gains-despite-q1-140600682.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 22:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/catalents-stock-gains-despite-q1-140600682.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share....</p>\n\n<a href=\"https://finance.yahoo.com/news/catalents-stock-gains-despite-q1-140600682.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTLT","symbol_name":"Catalent","start_time":0,"source_url":"https://finance.yahoo.com/news/catalents-stock-gains-despite-q1-140600682.html","article_id":"2481989127","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4lmvToGK4d2FNc0SIOXMvw--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/51f0c2cd09522c9a15cba48260e4facf"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481989127","pubTimestamp":1730901960,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share.The company’s GAAP loss per share was 71 cents during the quarter, narrower than the year-ago period’s loss of $4.19 per share.Revenues grossed $1.02 billion in the reported quarter, up 4.2% year over year. However, the metric lagged the Zacks Consensus Estimate by 5.3%.At constant exchange rate or CER, revenues were also up 4%, primarily driven by growth in the manufacture of prescription products, increased demand for orally disintegrating Zydis commercial products and gene therapy offerings. However, this was partially offset by a decline in demand for COVID-19-related programs.After excluding COVID-related revenues in the first quarter of fiscal 2025, net revenues increased 13% year over year.Shares of this company were up nearly 2.6% in yesterday’s after-hours trading.Find the latest ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CTLT":"Catalent","DGX":"奎斯特诊疗","RMD.AU":"Resmed DRC","RMD":"瑞思迈","BSX":"波士顿科学"},"translate_title":"尽管第一季度盈利未达预期，康泰伦特股价仍上涨，毛利率上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":1,"BSX":0.9,"DGX":0.9,"RMD":0.9,"RMD.AU":0.9},"content_text":"Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per share.  \nThe company’s GAAP loss per share was 71 cents during the quarter, narrower than the year-ago period’s loss of $4.19 per share.\nCatalent’s Revenues in Detail\nRevenues grossed $1.02 billion in the reported quarter, up 4.2% year over year. However, the metric lagged the Zacks Consensus Estimate by 5.3%.\nAt constant exchange rate or CER, revenues were also up 4%, primarily driven by growth in the manufacture of prescription products, increased demand for orally disintegrating Zydis commercial products and gene therapy offerings. However, this was partially offset by a decline in demand for COVID-19-related programs.\nAfter excluding COVID-related revenues in the first quarter of fiscal 2025, net revenues increased 13% year over year.\nThe top line was driven by strength in both the Biologics and Pharma and Consumer Health (PCH) segment.\nShares of this company were up nearly 2.6% in yesterday’s after-hours trading.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nCTLT’s Segments in Detail\nCatalent reports via two segments — Biologics and PCH.Revenues in the Biologics segment rose 2.9% year over year on a reported basis (up 3% at CER) to $461 million in the quarter under review.\nRevenues in the PCH segment increased 5.4% from the year-ago period (up 5% at CER) to $563 million.\nCatalent’s Geographic Performance\nGeographically, CTLT operates via three regions — the United States, Europe and Other.\nRevenues from the United States were $658 million (up 2% year over year), while revenues from Europe were $331 million (up 20.8% year over year).\nRevenues from Other region declined 22.7% year over year to $68 million.\n\nCatalent, Inc. Price, Consensus and EPS Surprise\n  \nCatalent, Inc. price-consensus-eps-surprise-chart | Catalent, Inc. Quote\n\nCTLT’s Operational Update\nIn the quarter under review, Catalent’s gross profit rose 7.1% to $181 million year over year. The gross margin expanded 48 basis points to 17.7%.\nSelling, general and administrative expenses rose 22.9% to $252 million year over year.\nAdjusted operating loss totaled $71 million compared with the prior-year quarter’s adjusted operating loss of $36 million.\nCatalent’s Financial Update\nCatalent exited first-quarter fiscal 2025 with cash and cash equivalents of $335 million compared with $289 million at the end of fiscal 2024. Total debt at the first quarter of fiscal 2025-end was $4.93 billion compared with $4.91 billion at the end of fiscal 2024.\nNet cash provided by operating activities at the end of first-quarter fiscal 2025 was $61 million against net cash used in operating activities of $70 million a year ago.\nCTLT’s Guidance\nCatalent will not provide any outlook in light of the pending transaction with Novo Holdings.\nOur Take\nCatalent exited the first quarter of fiscal 2025 with solid year-over-year improvement in its overall top-line results. The revenue uptick in both segments and the majority of geographic regions were impressive as well. The continued strength in CTLT’s Zydis commercial products and gene therapy offerings buoys optimism. The gross margin expansion was an added plus.\nHowever, Catalent’s lower-than-expected results and lower revenues from the Other region in the fiscal first quarter were disappointing. The company continued to face escalating operating costs during the quarter, which was discouraging.\nCatalent’s Zacks Rank and Key Picks\nCTLT currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Incorporated DGX, ResMed Inc. RMD and Boston Scientific Corporation BSX.\nQuest Diagnostics, carrying a Zacks Rank of 2 (Buy), reported third-quarter 2024 adjusted earnings per share (EPS) of $2.30, beating the Zacks Consensus Estimate by 1.8%. Revenues of $2.49 billion outpaced the consensus mark by 3.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nQuest Diagnostics has a long-term estimated growth rate of 6.5%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.4%.\nResMed reported first-quarter fiscal 2025 adjusted EPS of $2.20, beating the Zacks Consensus Estimate by 8.4%. Revenues of $1.22 billion surpassed the Zacks Consensus Estimate by 2.9%. It currently carries a Zacks Rank #2.\nResMed has a long-term estimated growth rate of 14.8%. RMD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.4%.\nBoston Scientific reported third-quarter 2024 adjusted EPS of 63 cents, beating the Zacks Consensus Estimate by 8.6%. Revenues of $4.21 billion surpassed the Zacks Consensus Estimate by 4.4%. It currently carries a Zacks Rank #2.\nBoston Scientific has a long-term estimated growth rate of 13.8%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nCatalent, Inc. (CTLT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481989127"}